In this issue:
Addition of tafasitamab and lenalidomide to R-CHOP
Real-world patient-centred data about treatment-related time burden and preferences
Final results from the phase II PRIMO trial
Combination of rituximab, acalabrutinib and durvalumab
Modern mediastinal RT and its association with subsequent malignant neoplasms
Safety and efficacy of epcoritamab monotherapy
Investigation of immunodeficiency-associated PCNSL
Long-term quality of life for those with HL
Efficacy, CNS penetration, and molecular response dynamics of glofitamab
MRD and PFS
Please login below to download this issue (PDF)